MedPath

The STEPS - Totalis™ Trial

Not Applicable
Completed
Conditions
Lumbar Spinal Stenosis
Interventions
Device: Totalis
Procedure: Comparator Surgical Procedure
Registration Number
NCT02079038
Lead Sponsor
VertiFlex, Incorporated
Brief Summary

The purpose of this study is to determine safety and effectiveness, as measured by changes in pain, disability, patient satisfaction, and claudicatory symptoms, at 6 months following treatment with the Totalis™ Direct Decompression System or Sham Comparator Surgical Procedure in patients with lumbar spinal stenosis

Detailed Description

Subjects suffering from symptoms of neurogenic intermittent claudication secondary to a radiographically-confirmed diagnosis of central canal stenosis, with or without mild or moderate lateral recess stenosis, at one or two levels from L1 to L5 who meet all inclusion/exclusion criteria, including ≥6 months of non-operative management.

Patients included in the clinical investigation will return for follow-up visits at 1 week for safety evaluation, and at 6 weeks, 3 months, 6 months, 12 months, 18 months and 24 months post-treatment to collect data for evaluation of safety and effectiveness.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
180
Inclusion Criteria
  • Male or female subjects greater than or equal to 55 years of age
  • Neurogenic intermittent claudication (NIC) symptoms defined generally as leg/buttock/ groin pain and/or paresthesias that are exacerbated with standing and walking and relieved by flexion
  • VAS leg symptom severity >50 (in either leg) during episodes of neurogenic claudication
  • Subjects who are able to walk a minimum of 50 feet without experiencing NIC symptoms
  • Diagnosis of central canal spinal stenosis, with or without mild to moderate lateral recess stenosis, at one or two levels from L1-L5 with radiologic evidence
  • Subjects with persistent lumbar spinal stenosis symptoms that, during the course of the last year, have been unresponsive to a minimum of 6 months of conservative therapy
Exclusion Criteria
  • Significant back, buttock or leg pain from causes other than lumbar central canal stenosis
  • Axial back pain only
  • Severe foraminal stenosis at index level(s) and/or symptomatic foraminal stenosis at any lumbar level
  • Severe lateral recess stenosis
  • Lumbar spinal stenosis at more than two levels determined pre-operatively to require surgical intervention
  • Prior decompressive surgery at index level (s) or fusion at any lumbar level
  • Epidural steroid or nerve block steroid injection at index level(s) within 6 weeks of baseline assessments
  • Spondylolisthesis (anterolisthesis or retrolisthesis) greater than grade 1
  • Spondylolysis (pars fracture)
  • Significant degenerative lumbar scoliosis at index level(s)
  • Morbid obesity
  • Significant peripheral vascular disease
  • Active significant co-morbidity
  • Undergoing immunosuppressive therapy or long-term steroid use
  • Current spinal cord stimulator or implanted pain pump
  • Life expectancy less than 2 years
  • Evidence of substance abuse within the year
  • Involvement or potential involvement in litigation related to the spine or worker's compensation related to a back and/or leg issue

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Totalis™ Direct Decompression ProcedureTotalisTotalis
Comparator ProcedureComparator Surgical ProcedureComparator Surgical Procedure
Primary Outcome Measures
NameTimeMethod
Percentage of Subjects With Clinically Significant Improvement in OutcomesBaseline and 6 Months

Where clinically significant improvement in outcomes is defined as improvement in any 2 of the 3 domains of the Zurich Claudication Questionnaire ( ZCQ)

* Improvement in physical function by ≥ 0.5 points from baseline

* Improvement in symptom severity by ≥ 0.5 points from baseline

* Patient Satisfaction Score of \< 2.5 points

And no interventions of the following nature through 6 months:

* Re-operations or revisions at index level(s) intended to treat stenosis

* Epidural steroid injection or selective nerve root block at index level(s)

And no unblindings

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (19)

Integrated Pain Management Medical Group, Inc.

🇺🇸

Walnut Creek, California, United States

GWU - Medical Faculty Associates, Inc.

🇺🇸

Washington, District of Columbia, United States

Arizona Pain Specialists

🇺🇸

Scottsdale, Arizona, United States

Performance Spine and Sports Physicians, PC

🇺🇸

Pottstown, Pennsylvania, United States

Spine Team Texas

🇺🇸

Southlake, Texas, United States

Virginia iSpine Physicians PC

🇺🇸

Richmond, Virginia, United States

Florida Pain Institute

🇺🇸

Merritt Island, Florida, United States

Pain Management Associates

🇺🇸

Independence, Missouri, United States

University Pain Medicine Center

🇺🇸

Somerset, New Jersey, United States

Medhat Mikhael, M.D. Inc.

🇺🇸

Fountain Valley, California, United States

Holy Cross Hospital

🇺🇸

Fort Lauderdale, Florida, United States

Penn State Hershey Medical Center

🇺🇸

Hershey, Pennsylvania, United States

Alabama Clinical Therapeutics

🇺🇸

Birmingham, Alabama, United States

Hope Research Institute

🇺🇸

Phoenix, Arizona, United States

Oklahoma Pain Physicians

🇺🇸

Oklahoma City, Oklahoma, United States

SC Pain & Spine Specialists

🇺🇸

Murrells Inlet, South Carolina, United States

Orthopedic Pain Specialists

🇺🇸

Santa Monica, California, United States

American Health Network

🇺🇸

Muncie, Indiana, United States

Pain Care, LLC

🇺🇸

Stockbridge, Georgia, United States

© Copyright 2025. All Rights Reserved by MedPath